- Report
- August 2025
- 184 Pages
Global
From €3179EUR$3,545USD£2,750GBP
€3533EUR$3,939USD£3,056GBP
- Report
- August 2025
- 183 Pages
Global
From €3179EUR$3,545USD£2,750GBP
€3533EUR$3,939USD£3,056GBP
- Report
- February 2026
- 200 Pages
Global
From €2682EUR$2,990USD£2,320GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- November 2025
- 200 Pages
Global
From €7130EUR$7,950USD£6,168GBP
- Report
- July 2025
- 101 Pages
Global
From €3500EUR$4,181USD£3,134GBP
- Report
- May 2024
- 129 Pages
Global
From €3586EUR$3,999USD£3,103GBP
- Report
- August 2023
- 145 Pages
Global
From €2825EUR$3,150USD£2,444GBP
- Report
- November 2023
- 30 Pages
United States
From €2466EUR$2,750USD£2,134GBP
- Report
- May 2024
- 136 Pages
Global
From €3586EUR$3,999USD£3,103GBP
- Report
- July 2024
- 100 Pages
Global
From €3363EUR$3,750USD£2,909GBP
- Report
- March 2024
- 303 Pages
Global
From €7130EUR$7,950USD£6,168GBP
- Report
- March 2021
- 149 Pages
Global
From €6233EUR$6,950USD£5,392GBP
- Report
- September 2022
- 392 Pages
Global
From €3229EUR$3,600USD£2,793GBP

Loteprednol is a topical corticosteroid used to treat a variety of ocular disorders, including allergic conjunctivitis, vernal keratoconjunctivitis, and post-operative inflammation. It is available in both ophthalmic suspension and ointment forms. Loteprednol is a synthetic corticosteroid that works by reducing inflammation and suppressing the immune system. It is used to reduce the symptoms of eye inflammation, such as redness, itching, and swelling.
Loteprednol is a popular choice for treating ocular disorders due to its low risk of side effects and its ability to reduce inflammation quickly. It is also used to treat dry eye syndrome, a condition that can cause discomfort and blurred vision. Loteprednol is available in both generic and brand-name forms.
The Loteprednol market is a competitive one, with many companies offering products for the treatment of ocular disorders. Some of the companies in the market include Allergan, Bausch + Lomb, Merck, Novartis, and Pfizer. Show Less Read more